US regulator investigates tumour risk in children given Novartis gene therapy
新聞摘要
以下為來源提供的節錄，完整報道請查看原文。
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma.
The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy.
The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy.